Video

Q&A With Robert Giugliano From Brigham and Women's: PCSK9 Inhibitors Provide Hope for Cardiac Patients

Author(s):

It was less than two decades ago that researchers uncovered the role of PCSK9 in a person's body. In just the past few months two new medications have been developed that could go a long way in helping win the fight against bad cholesterol.

It was less than two decades ago that researchers uncovered the role of PCSK9 in a person's body. In just the past few months two new medications have been developed that could go a long way in helping win the fight against bad cholesterol.

Robert Giugliano, MD, from Brigham and Women's Hospital discussed the early stages of the medication and what it can mean for treatment of patients going forward during the European Society of Cardiology's annual meeting in London.

Related Videos
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
Jörn Schattenberg, MD | Credit: Novo Nordisk
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
© 2024 MJH Life Sciences

All rights reserved.